Schwab Hits Record $12T Assets as MaxCyte Navigates Biotech Rationalization
Charles Schwab reported record-breaking 2025 results with $12 trillion in client assets and a 50% surge in adjusted EPS, signaling a powerful recovery in the brokerage sector. Conversely, life sciences firm MaxCyte is navigating a 15% revenue decline as cell therapy customers consolidate programs and reduce capital expenditures.